{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:16:23Z","timestamp":1791317783434,"version":"4.3.1"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Interleukin-33 (IL-33) is a nuclear factor mainly expressed in barrier epithelium, endothelial cells, and fibroblast reticular cells. Some inflammatory cells also express IL-33 under certain conditions. The important role of IL-33 in allergic reactions, helminth infection, cancer, tissue fibrosis, chronic inflammation, organ transplantation, and rheumatic immune diseases has been extensively studied in recent years. IL-33 primarily activates various circulating and tissue-resident immune cells, including mast cell, group 2 innate lymphoid cell (ILC2), regulatory T cell (Treg), T helper 2 cell (Th2), natural killer cell (NK cell), and macrophage. Therefore, IL-33 plays an immunomodulatory role and shows pleiotropic activity in different immune microenvironments. The IL-33\/serum stimulation-2 (ST2) axis has been shown to have a detrimental effect on rheumatoid arthritis, systemic lupus erythematosus, and other rheumatic diseases. Interestingly, IL-33 also plays a protective role in the repair of barrier epithelium and the activation of Tregs. Therefore, the role of IL-33\/ST2 depends on the underlying pathological conditions in rheumatic diseases. This review focuses on the dual role of the IL-33\/ST2 axis in rheumatic diseases.<\/jats:p>","DOI":"10.3389\/fmed.2021.739489","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:41:48Z","timestamp":1631493708000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["IL-33 in Rheumatic Diseases"],"prefix":"10.3389","volume":"8","author":[{"given":"Yuanji","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","article-title":"Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules","volume":"163","author":"Baekkevold","year":"2003","journal-title":"Am J Pathol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity."},{"key":"B3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/cmi.2016.34","article-title":"HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins","volume":"14","author":"Bertheloot","year":"2017","journal-title":"Cell Mol Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","article-title":"Interleukin-33 in tissue homeostasis, injury, and inflammation","volume":"42","author":"Molofsky","year":"2015","journal-title":"Immunity."},{"key":"B8","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature10540","article-title":"Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules","volume":"479","author":"Moussion","year":"2011","journal-title":"Nature."},{"key":"B9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nri3298","article-title":"HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes","volume":"12","author":"Girard","year":"2012","journal-title":"Nat Rev Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cytogfr.2019.04.004","article-title":"The role of the IL-33\/ST2 axis in autoimmune disorders: friend or foe?","volume":"50","author":"Liu","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e3331","DOI":"10.1371\/journal.pone.0003331","article-title":"The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel \u2018alarmin'?","volume":"3","author":"Moussion","year":"2008","journal-title":"PLoS ONE."},{"key":"B12","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.4049\/jimmunol.1101977","article-title":"Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain","volume":"188","author":"Pichery","year":"2012","journal-title":"J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6941","DOI":"10.1074\/jbc.M111.298703","article-title":"Interleukin 33 as a mechanically responsive cytokine secreted by living cells","volume":"287","author":"Kakkar","year":"2012","journal-title":"J Biol Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/embor.2008.145","article-title":"Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket","volume":"9","author":"Roussel","year":"2008","journal-title":"Embo Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaut.2014.02.012","article-title":"Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation","volume":"55","author":"Bessa","year":"2014","journal-title":"J Autoimmun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3389\/fimmu.2017.00722","article-title":"Full length interleukin 33 aggravates radiation-induced skin reaction","volume":"8","author":"Kurow","year":"2017","journal-title":"Front Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"19420","DOI":"10.1074\/jbc.M901744200","article-title":"Interleukin-33 is biologically active independently of caspase-1 cleavage","volume":"284","author":"Talabot-Ayer","year":"2009","journal-title":"J Biol Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1073\/pnas.0812690106","article-title":"The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1","volume":"106","author":"Cayrol","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefrancais","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B20","doi-asserted-by":"publisher","first-page":"15502","DOI":"10.1073\/pnas.1410700111","article-title":"Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells","volume":"111","author":"Lefrancais","year":"2014","journal-title":"Proc Natl Acad Sci USA."},{"key":"B21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/mi.2012.129","article-title":"Mast cell chymase modulates IL-33 levels and controls allergic sensitization in dust-mite induced airway inflammation","volume":"6","author":"Waern","year":"2013","journal-title":"Mucosal Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.immuni.2009.05.007","article-title":"Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases","volume":"31","year":"2009","journal-title":"Immunity."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1038\/ncomms9327","article-title":"Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation","volume":"6","author":"Cohen","year":"2015","journal-title":"Nat Commun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.jaci.2016.03.056","article-title":"IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells","volume":"138","author":"Galand","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jdermsci.2014.01.009","article-title":"Immediate-type contact hypersensitivity is reduced in interleukin-33 knockout mice","volume":"74","author":"Imai","year":"2014","journal-title":"J Dermatol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/jid.2015.85","article-title":"Epidermal expression and regulation of interleukin-33 during homeostasis and inflammation: strong species differences","volume":"135","author":"Sundnes","year":"2015","journal-title":"J Invest Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2353\/ajpath.2008.080014","article-title":"Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation","volume":"173","author":"Kuchler","year":"2008","journal-title":"Am J Pathol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/ni.2045","article-title":"Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity","volume":"12","author":"Chang","year":"2011","journal-title":"Nat Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jaci.2011.10.036","article-title":"Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity","volume":"129","author":"Kim","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.20110079","article-title":"Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection","volume":"209","author":"Wills-Karp","year":"2012","journal-title":"J Exp Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.4049\/jimmunol.1300490","article-title":"Macrophage-derived IL-33 is a critical factor for placental growth","volume":"191","author":"Fock","year":"2013","journal-title":"J Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e11944","DOI":"10.1371\/journal.pone.0011944","article-title":"IL-33 is produced by mast cells and regulates IgE-dependent inflammation","volume":"5","author":"Hsu","year":"2010","journal-title":"PLoS ONE."},{"key":"B33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/jir.2012.0066","article-title":"Murine mast cells secrete and respond to interleukin-33","volume":"34","author":"Tung","year":"2014","journal-title":"J Interferon Cytokine Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.immuni.2017.04.017","article-title":"M, Ishiwata K, Hisaeda H, Kurashima Y, et al","volume":"46","year":"2017"},{"key":"B35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/thoraxjnl-2015-207728","article-title":"The histone deacetylase inhibitor trichostatin A suppresses murine innate allergic inflammation by blocking group 2 innate lymphoid cell (ILC2) activation","volume":"71","author":"Toki","year":"2016","journal-title":"Thorax."},{"key":"B36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 axis in immune cells during inflammatory diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"27905","DOI":"10.1074\/jbc.270.46.27905","article-title":"ST2\/T1 protein functionally binds to two secreted proteins from Balb\/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1","volume":"270","author":"Kumar","year":"1995","journal-title":"J Biol Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1006\/bbrc.1997.6810","article-title":"Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli","volume":"235","author":"Kumar","year":"1997","journal-title":"Biochem Biophys Res Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0014-5793(93)81333-U","article-title":"Presence of a novel primary response gene ST2L, encoding a product highly similar to the interleukin 1 receptor type 1","volume":"318","author":"Yanagisawa","year":"1993","journal-title":"Febs Lett"},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1006\/bbrc.1999.1469","article-title":"Presence and expression of a novel variant form of ST2 gene product in human leukemic cell line UT-7\/GM","volume":"264","author":"Tominaga","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.cyto.2008.03.008","article-title":"The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33","volume":"42","author":"Palmer","year":"2008","journal-title":"Cytokine."},{"key":"B42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov."},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cytogfr.2017.09.005","article-title":"Pathophysiology of IL-33 and IL-17 in allergic disorders","volume":"38","author":"Gupta","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"B44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cytogfr.2015.07.017","article-title":"The IL-33\/ST2 axis: Role in health and disease","volume":"26","author":"De","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.it.2009.06.001","article-title":"TIR8\/SIGIRR: an IL-1R\/TLR family member with regulatory functions in inflammation and T cell polarization","volume":"30","author":"Garlanda","year":"2009","journal-title":"Trends Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3389\/fimmu.2020.01798","article-title":"Contributions of IL-33 in non-hematopoietic lung cells to obstructive lung disease","volume":"11","author":"Drake","year":"2020","journal-title":"Front Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.4049\/jimmunol.179.4.2051","article-title":"Cutting edge: The ST2 ligand IL-33 potently activates and drives maturation of human mast cells","volume":"179","author":"Allakhverdi","year":"2007","journal-title":"J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"L429","DOI":"10.1152\/ajplung.00252.2011","article-title":"IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice","volume":"302","author":"Cho","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.4049\/jimmunol.0803067","article-title":"IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex","volume":"183","author":"Espinassous","year":"2009","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/mi.2012.130","article-title":"Potential autocrine regulation of interleukin-33\/ST2 signaling of dendritic cells in allergic inflammation","volume":"6","author":"Su","year":"2013","journal-title":"Mucosal Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/JLB.3A0120-379RR","article-title":"IL-33 promotes type 1 cytokine expression via p38 MAPK in human NK cells","volume":"107","author":"Ochayon","year":"2020","journal-title":"J Leukoc Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e65614","DOI":"10.7554\/eLife.65614","article-title":"IL-33 promotes innate lymphoid cell-dependent IFN-gamma production required for innate immunity to Toxoplasma gondii","volume":"10","author":"Clark","year":"2021","journal-title":"Elife."},{"key":"B53","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/exd.12076","article-title":"Evidence for a regulatory loop between IFN-gamma and IL-33 in skin inflammation","volume":"22","author":"Seltmann","year":"2013","journal-title":"Exp Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3389\/fimmu.2018.02308","article-title":"The impact of invariant NKT cells in sterile inflammation: the possible contribution of the alarmin\/cytokine IL-33","volume":"9","author":"Ferhat","year":"2018","journal-title":"Front Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/exd.12833","article-title":"ST2 receptor invalidation maintains wound inflammation, delays healing and increases fibrosis","volume":"25","author":"Lee","year":"2016","journal-title":"Exp Dermatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3389\/fimmu.2018.02432","article-title":"IL-33\/ST2 axis in organ fibrosis","volume":"9","author":"Kotsiou","year":"2018","journal-title":"Front Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.3390\/ijms21155203","article-title":"The roles of immune cells in the pathogenesis of fibrosis","volume":"21","author":"Huang","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med."},{"key":"B59","first-page":"141","article-title":"Role of IL-33\/ST2 signaling pathway in systemic sclerosis and other fibrotic diseases","author":"Xu","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102756","article-title":"Pathophysiologic role of Interleukin-33\/ST2 in Sjogren's syndrome","author":"Soyfoo","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10238-010-0115-4","article-title":"Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population","volume":"11","author":"Yang","year":"2011","journal-title":"Clin Exp Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","article-title":"Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus","volume":"49","author":"Mok","year":"2010","journal-title":"Rheumatology."},{"key":"B63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.clim.2019.03.008","article-title":"Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus","volume":"202","author":"Guo","year":"2019","journal-title":"Clin Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1007\/s10753-013-9802-0","article-title":"IL-33 neutralization suppresses lupus disease in lupus-prone mice","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation."},{"key":"B65","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/art.24305","article-title":"Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis","volume":"60","author":"Palmer","year":"2009","journal-title":"Arthritis Rheum."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3346\/jkms.2011.26.9.1132","article-title":"Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis","volume":"26","author":"Hong","year":"2011","journal-title":"J Korean Med Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3899\/jrheum.090492","article-title":"Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis","volume":"37","author":"Matsuyama","year":"2010","journal-title":"J Rheumatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.12659\/MSM.907540","article-title":"Prognostic significance of serum interleukins and soluble ST2 in Traditional Chinese Medicine (TCM) syndrome-differentiated rheumatoid arthritis","volume":"24","author":"Wang","year":"2018","journal-title":"Med Sci Monit."},{"key":"B69","doi-asserted-by":"publisher","first-page":"10913","DOI":"10.1073\/pnas.0801898105","article-title":"IL-33 exacerbates antigen-induced arthritis by activating mast cells","volume":"105","author":"Xu","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00296-011-1854-6","article-title":"Sustained elevation of interleukin-33 in sera and synovial fluids from patients with rheumatoid arthritis non-responsive to anti-tumor necrosis factor: possible association with persistent IL-1beta signaling and a poor clinical response","volume":"32","author":"Matsuyama","year":"2012","journal-title":"Rheumatol Int."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3899\/jrheum.140234","article-title":"The Interleukin 33\/ST2 axis in patients with primary Sjogren syndrome: expression in serum and salivary glands, and the clinical association","volume":"42","author":"Jung","year":"2015","journal-title":"J Rheumatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-203187","article-title":"Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome","volume":"73","author":"Awada","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/ijo.IJO","article-title":"Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease","volume":"66","author":"Luo","year":"2018","journal-title":"Indian J Ophthalmol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10875-014-0037-0","article-title":"Early systemic sclerosis: serum profiling of factors involved in endothelial, T-cell, and fibroblast interplay is marked by elevated interleukin-33 levels","volume":"34","author":"Vettori","year":"2014","journal-title":"J Clin Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/sji.12317","article-title":"Increased serum levels of the IL-33 neutralizing sST2 in limited cutaneous systemic sclerosis","volume":"82","author":"Wagner","year":"2015","journal-title":"Scand J Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1136\/ard.2009.119321","article-title":"The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis","volume":"69","author":"Manetti","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jaci.2014.12.1932","article-title":"Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis","volume":"135","author":"MacDonald","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000471798","article-title":"new interleukins in psoriasis and psoriatic arthritis patients: the possible roles of interleukin-33 to interleukin-38 in disease activities and bone erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/eji.201646774","article-title":"Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage","volume":"47","author":"Raimondo","year":"2017","journal-title":"Eur J Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00011-020-01399-x","article-title":"IL-33 enhances macrophage release of IL-1beta and promotes pain and inflammation in gouty arthritis","volume":"69","author":"Fattori","year":"2020","journal-title":"Inflamm Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.7150\/thno.48028","article-title":"IL-33\/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain","volume":"10","author":"Yin","year":"2020","journal-title":"Theranostics."},{"key":"B84","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fendo.2019.00036","article-title":"IL-33 ameliorates the development of MSU-induced inflammation through expanding MDSCs-like cells","volume":"10","author":"Shang","year":"2019","journal-title":"Front Endocrinol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"42413","DOI":"10.1038\/srep42413","article-title":"Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease","volume":"7","author":"Furukawa","year":"2017","journal-title":"Sci Rep."},{"key":"B86","doi-asserted-by":"publisher","first-page":"14879","DOI":"10.1038\/s41598-020-71848-4","article-title":"Identification of serum IFN-alpha and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease","volume":"10","author":"Minaga","year":"2020","journal-title":"Sci Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/art.41052","article-title":"Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via toll-like receptor 7\/interleukin-33 signaling","volume":"72","author":"Ishiguro","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s10067-011-1843-x","article-title":"Serum levels of IL-33 is increased in patients with ankylosing spondylitis","volume":"30","author":"Han","year":"2011","journal-title":"Clin Rheumatol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/03009742.2012.735700","article-title":"Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis","volume":"42","author":"Li","year":"2013","journal-title":"Scand J Rheumatol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"631603","DOI":"10.3389\/fimmu.2021.631603","article-title":"IL-33 gene polymorphisms as potential biomarkers of disease susceptibility and response to TNF inhibitors in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis patients","volume":"12","author":"Iwaszko","year":"2021","journal-title":"Front Immunol."},{"key":"B91","first-page":"437","article-title":"Bone changes and curative effect of infliximab in patients with ankylosing spondylitis","volume":"20","author":"Li","year":"2020","journal-title":"J Musculoskelet Neuronal Interact."},{"key":"B92","first-page":"428","article-title":"Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis","volume":"31","author":"Yuan","year":"2013","journal-title":"Clin Exp Rheumatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00296-020-04554-z","article-title":"Interleukin-33\/suppression of tumorigenicity 2 (IL-33\/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study","volume":"40","author":"Opinc","year":"2020","journal-title":"Rheumatol Int."},{"key":"B94","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3899\/jrheum.170020","article-title":"serum levels of interleukin 33 and soluble ST2 are associated with the extent of disease activity and cutaneous manifestations in patients with active adult-onset still's disease","volume":"44","author":"Han","year":"2017","journal-title":"J Rheumatol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","article-title":"Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease","volume":"28","author":"Kim","year":"2013","journal-title":"J Korean Med Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.imlet.2018.11.005","article-title":"Interleukin-33 gene expression and rs1342326 polymorphism in Behcet's disease","volume":"212","author":"Talei","year":"2019","journal-title":"Immunol Lett."},{"key":"B97","doi-asserted-by":"publisher","first-page":"ITC81-ITC96","DOI":"10.7326\/AITC202006020","article-title":"Systemic Lupus Erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/annrheumdis-2015-208557","article-title":"Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjogren syndrome: comparison of different kits","volume":"75","author":"Riviere","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B99","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/08820139.2016.1193868","article-title":"Association between IL-33 gene polymorphisms (rs1929992, rs7044343) and systemic lupus erythematosus in a Chinese Han population","volume":"45","author":"Xu","year":"2016","journal-title":"Immunol Invest."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2016.07.001","article-title":"The association of novel IL-33 polymorphisms with sIL-33 and risk of systemic lupus erythematosus","volume":"77","author":"Guo","year":"2016","journal-title":"Mol Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1547578","DOI":"10.1155\/2019\/1547578","article-title":"Interaction between IL-33 gene polymorphisms and current smoking with susceptibility to systemic lupus erythematosus","volume":"2019","author":"Zhu","year":"2019","journal-title":"J Immunol Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jbspin.2010.08.017","article-title":"Cell and cytokine imbalances in rheumatoid synovitis","volume":"78","author":"Boissier","year":"2011","journal-title":"Joint Bone Spine."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3899\/jrheum.100184","article-title":"Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis","volume":"37","author":"Mu","year":"2010","journal-title":"J Rheumatol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cyto.2011.12.010","article-title":"Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis","volume":"58","author":"Xiangyang","year":"2012","journal-title":"Cytokine."},{"key":"B106","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/s10165-011-0480-1","article-title":"Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33","volume":"22","author":"Kageyama","year":"2012","journal-title":"Mod Rheumatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3892\/ijmm.2012.883","article-title":"IL-33 regulates TNF-alpha dependent effects in synovial fibroblasts","volume":"29","author":"Kunisch","year":"2012","journal-title":"Int J Mol Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"985301","DOI":"10.1155\/2013\/985301","article-title":"Increased IL-33 in synovial fluid and paired serum is associated with disease activity and autoantibodies in rheumatoid arthritis","volume":"2013","author":"Tang","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4049\/jimmunol.1502124","article-title":"In vivo expansion of activated Foxp3+ regulatory T cells and establishment of a type 2 immune response upon IL-33 treatment protect against experimental arthritis","volume":"197","author":"Biton","year":"2016","journal-title":"J Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B111","first-page":"1295","article-title":"The IL33\/ST2 axis in Sjogren syndrome in relation to disease activity","volume":"20","author":"Margiotta","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00296-018-4063-8","article-title":"Smoking, disease characteristics and serum cytokine levels in patients with primary Sjogren's syndrome","volume":"38","author":"Olsson","year":"2018","journal-title":"Rheumatol Int"},{"key":"B113","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cyto.2013.07.006","article-title":"Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's syndrome","volume":"64","author":"Zhao","year":"2013","journal-title":"Cytokine."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"key":"B115","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00296-015-3417-8","article-title":"The IL-33 gene is related to increased susceptibility to systemic sclerosis","volume":"36","author":"Koca","year":"2016","journal-title":"Rheumatol Int."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12026-016-8797-7","article-title":"Association of interleukin-1 family cytokines single nucleotide polymorphisms with susceptibility to systemic sclerosis: an independent case-control study and a meta-analysis","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","article-title":"International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials","volume":"76","author":"Orbai","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology."},{"key":"B119","doi-asserted-by":"publisher","first-page":"7158014","DOI":"10.1155\/2019\/7158014","article-title":"Possible roles of IL-33 in the innate-adaptive immune crosstalk of psoriasis pathogenesis","volume":"2019","author":"Cannavo","year":"2019","journal-title":"Mediators Inflamm."},{"key":"B120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jbspin.2011.02.011","article-title":"Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis","volume":"79","author":"Talabot-Ayer","year":"2012","journal-title":"Joint Bone Spine."},{"key":"B121","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13075-016-1042-x","article-title":"Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33","volume":"18","author":"Athari","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B122","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.4049\/jimmunol.1700060","article-title":"Chronic fibro-inflammatory responses in autoimmune pancreatitis depend on IFN-alpha and IL-33 produced by plasmacytoid dendritic cells","volume":"198","author":"Watanabe","year":"2017","journal-title":"J Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.14309\/ajg.0000000000000245","article-title":"The IFN-alpha-IL-33 axis as possible biomarkers in IgG4-related disease","volume":"114","author":"Minaga","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.39209","article-title":"Number of circulating follicular helper 2 T cells correlates with IgG4 and interleukin-4 levels and plasmablast numbers in IgG4-related disease","volume":"67","author":"Akiyama","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.739489\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:41:52Z","timestamp":1631493712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.739489\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":127,"alternative-id":["10.3389\/fmed.2021.739489"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.739489","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"article-number":"739489"}}